HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL from qol Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Masatoshi Kudo speaks to ecancer at ASCO 2023 about the results from the phase III IMbrave050 trial of adjuvant atezolizumab plus bevacizumab vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.nnHe reports that atezolizumab plus bevacizumab showed significant improvement over surveillance with a 12 month recurrence-free survival of 78% vs 65%.nnProf Kudo also explains that patient reported outcomes of qua
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)